Showing results (201-210 of 2,890) with videos related to
Sort By:
Pageof 289
Movement Disorders : Official Journal of the Movement Disorder Society|January 1, 1989
The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridineW R Gibb, M Terruli, A J Lees, et al.European Journal of Pharmacology|November 1, 1988
The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmosetJ A Temlett, P N Chong, W H Oertel, et al.Synapse (New York, N.Y.)|June 1, 1993
Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic studyK K Gnanalingham, L A Smith, A J Hunter, et al.European Journal of Pharmacology|August 25, 1992
Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal gangliaM D Taylor, M L De Ceballos, S Rose, et al.British Journal of Pharmacology|August 1, 1988
The interaction of substituted benzamides with brain benzodiazepine binding sites in vitroR W Horton, S Lowther, J Chivers, et al.Brain : a Journal of Neurology|September 1, 1977
Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepamD Chadwick, M Hallett, R Harris, et al.Journal of Neural Transmission|January 1, 1987
Alterations in cerebral glutamic acid decarboxylase and 3H-flunitrazepam binding during continuous treatment of rats for up to 1 year with haloperidol, sulpiride or clozapineN M Rupniak, S A Prestwich, R W Horton, et al.Psychopharmacology|April 2, 1999
Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosetsR K Pearce, M Jackson, D R Britton, et al.European Journal of Pharmacology|September 30, 1983
Elevation of circulating prolactin concentrations may not cause striatal dopamine receptor supersensitivityN Rupniak, M Hong, S Mansfield, et al.Journal of Neurology, Neurosurgery, and Psychiatry|February 1, 1977
Plasma DOPA levels and growth hormone response to levodopa in parkinsomismA Galea-Debono, P Jenner, C D Marsden, et al.Pageof 289